aplaviroc (GW873140, AK-602)

Introduction

Investigational agent, 2005

Indications

• HIV
• used in combination with Combivir (AZT/3TC) or Kaletra (lopinavir/ritonavir)

Dosage

200-800 mg PO BID

Adverse effects

• hepatotoxicity (severe hepatotoxity 0.5-1%) (clinical trials stopped over concerns of severe hepatotoxicity, 2005)

Mechanism of action

• CCR5 antagonist

More general terms

• antiviral agent

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3001322